Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sickle cell disease pathophysiology

C T Noguchi1, A N Schechter, G P Rodgers

  • 1Department of Health and Human Services, National Institutes of Health, Bethesda, Maryland 20892.

Bailliere'S Clinical Haematology
|March 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olfactomedin 4 deletion induces colon adenocarcinoma in Apc<sup>Min/+</sup> mice.

Oncogene·2016
Same author

Inhibitory effect of nitrite on coagulation processes demonstrated by thrombelastography.

Nitric oxide : biology and chemistry·2014
Same author

Expression of hGC-1 is correlated with differentiation of gastric carcinoma.

Histopathology·2007
Same author

Biomarker and drug-target discovery using proteomics in a new rat model of sepsis-induced acute renal failure.

Kidney international·2006
Same author

Renal pathology in hemizygous sickle cell mice.

Toxicologic pathology·2002
Same author

Pathophysiology of a sickle cell trait mouse model: human alpha(beta)(S) transgenes with one mouse beta-globin allele.

Blood cells, molecules & diseases·2002
Same journal

Current status of stem cell therapy and prospects for gene therapy for the disorders of globin synthesis.

Bailliere's clinical haematology·2000
Same journal

Pharmacological therapy.

Bailliere's clinical haematology·2000
Same journal

Prenatal diagnosis and screening of the haemoglobinopathies.

Bailliere's clinical haematology·2000
Same journal

Sickle cell disease: clinical management.

Bailliere's clinical haematology·2000
Same journal

Pathophysiology of sickle cell disease.

Bailliere's clinical haematology·2000
Same journal

Thalassaemia: clinical management.

Bailliere's clinical haematology·2000
See all related articles

Sickle cell disease involves sickle haemoglobin (HbS) polymerization in red blood cells, causing anemia and blood flow obstruction. Therapies aim to reduce HbS polymerization, often by increasing fetal haemoglobin (HbF).

Area of Science:

  • Hematology
  • Molecular Medicine
  • Pathophysiology

Background:

  • Sickle cell disease is characterized by the intracellular polymerization of sickle haemoglobin (HbS) in erythrocytes.
  • HbS polymerization reduces red blood cell flexibility, leading to microcirculatory obstruction and chronic anemia.
  • Factors influencing polymerization include intracellular HbS concentration, oxygen saturation, and HbF levels.

Purpose of the Study:

  • To explore the pathophysiological mechanisms of sickle cell disease, focusing on HbS polymerization.
  • To review current and emerging therapeutic strategies aimed at reducing HbS polymerization.
  • To highlight the role of fetal haemoglobin (HbF) elevation in managing sickle cell disease.

Main Methods:

  • Review of existing literature on sickle cell pathophysiology and therapeutic interventions.

Related Experiment Videos

  • Analysis of factors affecting HbS polymerization, including hemoglobin composition and red blood cell properties.
  • Examination of the impact of alpha-thalassemia and high HbF levels on disease severity.

    • Main Results:

    • HbS polymerization is the central event causing red blood cell rigidity and vaso-occlusion.
    • Elevating fetal haemoglobin (HbF) levels effectively reduces HbS polymerization.
    • Therapeutic agents like hydroxyurea and butyrate compounds increase HbF, decreasing HbS polymerization.

    Conclusions:

    • Understanding HbS polymerization is key to managing sickle cell disease.
    • Pharmacological elevation of HbF is a promising therapeutic strategy.
    • Ongoing research includes bone marrow transplantation and gene therapy for sickle cell disease.